Tenaya Therapeutics, Inc.
Tenaya Therapeutics is a U.S.-based clinical-stage biotechnology company focused on discovering and developing therapies for heart disease. Its pipeline includes gene therapies and small molecules built around human genetics, with programs aimed at both rare inherited cardiomyopathies and more prevalent cardiovascular conditions.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaAAV-based therapies designed to address inherited heart disease at the genetic level.
Oral or systemic drug candidates targeting heart failure and related indications.
Earlier-stage programs using gene addition, editing, silencing and regeneration approaches.
Internal and partnered capabilities for AAV process development, QC and clinical supply.
Asiakkaat
Tenaya does not sell commercial products today; its near-term customers are clinical trial participants, investigators, hospitals and research sites that support development of its product candidates. If approved, its therapies would be used by cardiologists and specialty centers treating patients with inherited cardiomyopathies, arrhythmogenic disease and heart failure. In a commercial setting, reimbursement decisions by payors and treatment adoption by physicians would be critical to uptake.
Patients enrolled in MyPEAK-1, RIDGE-1 and other studies to evaluate safety and activity.
Hospitals, academic centers and investigators that administer and monitor studies.
Potential future prescribers for approved therapies in inherited cardiomyopathy and HFpEF.
Commercial and government payors that would determine reimbursement and access.
Potential collaborators for late-stage development and commercialization of TN-301 and other assets.
Strategia
Tenaya’s strategy is to build disease-modifying therapies for heart disease using human genetics, AAV gene therapy and complementary small-molecule approaches. It is prioritizing clinical data generation for lead programs, internal and partnered manufacturing capabilities, and selective partnering for larger indications where global commercialization resources matter.
Clinical readouts are needed to validate the platform and support regulatory advancement.
Development-stage biotech requires capital to fund trials, manufacturing and regulatory work.
Gene therapies require reliable AAV supply, quality control and scale-up capability.
Broader diseases such as HFpEF may require global resources for late-stage development and launch.
Maantiede
Tenaya is headquartered in South San Francisco, California and incorporated in Delaware, with operations centered in the United States. Its development, manufacturing and clinical activities are primarily U.S.-based, while future commercialization and regulatory filings could extend to Europe and other foreign markets through partners or direct approvals.
Riskit
Tenaya faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory approval risk, dependence on third parties and the need for substantial future capital. Its gene-therapy focus also adds manufacturing, quality and intellectual-property complexity, while commercial success would depend on physician adoption and payor reimbursement.
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
Lead programs may not demonstrate sufficient safety or efficacy to advance.
Kohdistuu - Capital dependenceVaikutus: KorkeaTodennäköisyys: Korkea
The company has not generated product revenue and relies on external financing.
Kohdistuu: Corporate funding and trial execution
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Gene and small-molecule candidates require lengthy, uncertain FDA and foreign review.
Kohdistuu: All pipeline programs
- Manufacturing and supply chain executionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
AAV therapies require consistent process control, quality and supply availability.
Kohdistuu: Clinical and future commercial supply
- Intellectual property competitionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Competing therapies and patent challenges could reduce the value of the pipeline.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätClinical and preclinical vendor costs are estimated before final invoices arrive, affecting period expense.
Vaikutus: Can create quarter-to-quarter volatility in operating loss
Equity awards to employees and directors are a significant non-cash cost in development-stage biotech.
Vaikutus: Affects reported operating expenses and loss per share
Cash invested in securities must be marked and classified appropriately, affecting interest income and OCI.
Vaikutus: Can influence liquidity presentation and non-operating results
Contractual obligations and accrual estimates affect liabilities and future cash needs.
Vaikutus: Important for assessing runway and spending cadence
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Lexeo Therapeutics, Inc.
LXEO · Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics is a U.S.-based clinical-stage biotechnology company developing gene therapy candidates for serious cardiovascular and neuromuscular diseases.
Tenax Therapeutics, Inc
TENX · Pharmaceutical Preparations
Taysha Gene Therapies, Inc.
TSHA · Biological Products, (No Diagnostic Substances)
Rocket Pharmaceuticals, Inc
RCKT · Pharmaceutical Preparations
Rocket Pharmaceuticals is a U.S.-based late-stage biotechnology company focused on developing genetic therapies for rare inherited diseases.
Benitec Biopharma Inc.
BNTC · Pharmaceutical Preparations
MeiraGTx Holdings plc
MGTX · Biological Products, (No Diagnostic Substances)
MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing adeno-associated virus (AAV) gene therapies for inherited retinal disease,…
Päivitetty: 24.9.2026